| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
Isocanadine, as an isomer of canadine, is expected to interact with similar molecular targets as other protoberberine alkaloids. These compounds are known to interact with various receptors, ion channels, and enzymes, including dopamine receptors, serotonin receptors, and acetylcholinesterase. Canadine has been reported to have effects on the central nervous system, including sedative, anxiolytic, and analgesic activities. Isocanadine may share some of these activities, though its specific targets and mechanisms of action are not well characterized. As a research compound, Isocanadine is used to study the pharmacology of benzylisoquinoline alkaloids and to explore the structure-activity relationships within this class of compounds.
|
|---|---|
| ln Vitro |
In vitro studies on Isocanadine are limited, as the compound is primarily used as a research chemical for studying alkaloid chemistry and pharmacology. As an isomer of canadine, Isocanadine may exhibit similar in vitro activities, such as inhibition of acetylcholinesterase or interaction with dopamine receptors. However, specific in vitro data for Isocanadine are not extensively documented in publicly available sources. The compound is typically used in studies comparing the activities of different protoberberine alkaloids and their isomers. Further in vitro studies are needed to fully characterize the biological activities of Isocanadine.
|
| ln Vivo |
In vivo studies on Isocanadine are limited, as the compound is primarily used as a research chemical. As an isomer of canadine, Isocanadine may exhibit similar in vivo activities, such as sedative, anxiolytic, or analgesic effects. However, specific in vivo data for Isocanadine are not extensively documented in publicly available sources. The compound is typically used in studies comparing the pharmacological profiles of different protoberberine alkaloids and their isomers. Further in vivo studies are needed to fully characterize the biological activities and therapeutic potential of Isocanadine.
|
| Enzyme Assay |
Non-cellular assays for Isocanadine are not well documented, as the compound is primarily used as a research chemical. However, standard assays for alkaloids may include receptor binding assays (e.g., dopamine receptor, serotonin receptor) and enzyme inhibition assays (e.g., acetylcholinesterase inhibition). These assays typically use purified receptors or enzymes and measure the binding affinity or inhibitory activity of the compound. Isocanadine would be tested at various concentrations to determine its IC50 or Ki values. These assays are essential for characterizing the pharmacological profile of the compound and for comparing its activities to those of other protoberberine alkaloids.
|
| Cell Assay |
In vitro cell-based assays for Isocanadine are not well documented, as the compound is primarily used as a research chemical. However, standard cell-based assays for alkaloids may include cytotoxicity assays, neuroprotection assays, and assays for neurotransmitter uptake or release. These assays typically use cell lines such as neuronal cells, cancer cells, or other relevant cell types. Cells are cultured in appropriate media and treated with Isocanadine at various concentrations. Cell viability, neurotransmitter levels, or other endpoints are measured to assess the compound's effects. However, specific published in vitro data for Isocanadine are not extensively documented.
|
| Animal Protocol |
In vivo animal studies for Isocanadine are not well documented, as the compound is primarily used as a research chemical. However, standard animal studies for alkaloids may include models of pain, anxiety, or neurological disorders. Animals would be treated with Isocanadine at various doses, and behavioral, physiological, or biochemical endpoints would be assessed. However, specific published in vivo data for Isocanadine are not extensively documented. The compound is primarily used in research to study the pharmacology of benzylisoquinoline alkaloids and to explore structure-activity relationships within this class of compounds.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Isocanadine are limited, as the compound is primarily used as a research chemical. As a small molecule alkaloid with a molecular weight of 339.39 g/mol, Isocanadine is expected to be absorbed from the gastrointestinal tract and distributed to tissues. However, detailed PK parameters such as half-life, Cmax, AUC, and bioavailability have not been extensively reported. The compound's solubility and stability are important factors for its use in in vitro and in vivo studies. Research-grade Isocanadine is intended for laboratory use only. Further pharmacokinetic studies are needed to fully characterize the compound's absorption, distribution, metabolism, and excretion.
|
| Toxicity/Toxicokinetics |
Toxicological data for Isocanadine are limited, as the compound is primarily used as a research chemical. As a naturally occurring alkaloid, Isocanadine may have toxic effects at high doses, as is the case with many alkaloids. However, specific toxicological data for Isocanadine are not extensively documented in publicly available sources. The compound is intended for laboratory use only and is not for human consumption. As with all research chemicals, appropriate safety precautions should be taken when handling Isocanadine.
|
| Additional Infomation |
Isocanadine is an isomer of canadine, a benzylisoquinoline alkaloid of the protoberberine subgroup. It has the molecular formula C20H21NO4 and CAS number 6656-19-5. Isocanadine is found in plants from the Papaveraceae family. As a research compound, it is used to study the pharmacology and structure-activity relationships of benzylisoquinoline alkaloids. Isocanadine is not approved for clinical use and is strictly a research chemical.
|
| Molecular Formula |
C20H21NO4
|
|---|---|
| Molecular Weight |
339.38504576683
|
| Exact Mass |
339.147
|
| CAS # |
6656-19-5
|
| Related CAS # |
522-97-4;6656-19-5;
|
| PubChem CID |
3471176
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.1
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
25
|
| Complexity |
488
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C=C2CN3CCC4=CC5=C(C=C4C3CC2=C1)OCO5)OC
|
| InChi Key |
HCRLQVVXDCKIFD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H21NO4/c1-22-17-7-13-5-16-15-9-20-19(24-11-25-20)6-12(15)3-4-21(16)10-14(13)8-18(17)23-2/h6-9,16H,3-5,10-11H2,1-2H3
|
| Chemical Name |
5,8,13,13a-Tetrahydro-10,11-dimethoxy-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine
|
| Synonyms |
(±)-Isocanadine Tetrahydropseudoberberine DC037021
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9465 mL | 14.7323 mL | 29.4646 mL | |
| 5 mM | 0.5893 mL | 2.9465 mL | 5.8929 mL | |
| 10 mM | 0.2946 mL | 1.4732 mL | 2.9465 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
